PolyPid’s (PYPD) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PolyPid (NASDAQ:PYPD) in a research note issued to investors on Tuesday, Marketbeat.com reports. HC Wainwright currently has a $13.00 price target on the stock. HC Wainwright also issued estimates for PolyPid’s Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($0.84) EPS, FY2028 earnings at ($0.40) EPS, FY2029 earnings at $0.80 EPS and FY2030 earnings at $1.64 EPS.

Separately, Weiss Ratings raised shares of PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $11.33.

PolyPid Stock Up 6.0%

Shares of PYPD stock opened at $4.24 on Tuesday. The stock has a market cap of $80.90 million, a price-to-earnings ratio of -2.22 and a beta of 1.40. The business’s fifty day moving average is $4.85 and its 200 day moving average is $4.58. PolyPid has a twelve month low of $3.06 and a twelve month high of $5.73.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.12. Equities research analysts expect that PolyPid will post -1.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PolyPid

Hedge funds have recently added to or reduced their stakes in the company. AIGH Capital Management LLC boosted its stake in PolyPid by 18.7% during the 1st quarter. AIGH Capital Management LLC now owns 1,593,587 shares of the company’s stock valued at $6,980,000 after purchasing an additional 250,615 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of PolyPid in the fourth quarter worth $451,000. XTX Topco Ltd lifted its holdings in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of PolyPid during the first quarter valued at $81,000. Finally, Jane Street Group LLC purchased a new stake in shares of PolyPid during the fourth quarter valued at $66,000. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting PolyPid

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $13.00 price target on PolyPid, which can help reinforce investor confidence in the stock’s upside potential.
• Positive Sentiment: The firm also raised near-term Q2 2026 EPS estimates and slightly improved its Q4 2026 EPS forecast, signaling modestly better expectations for execution in the coming quarters.
• Neutral Sentiment: HC Wainwright’s broader note updated multiple forward estimates across FY2026-FY2030, keeping attention on PolyPid’s long-term path to profitability. Article Title
• Negative Sentiment: Some longer-dated earnings forecasts were cut, including FY2027, FY2028, FY2029, and FY2030 EPS estimates, which suggests analysts still see a bumpy road to sustained earnings growth. Article Title

About PolyPid

PolyPid Ltd is a clinical?stage biotechnology company focused on polymer?based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus?Penetrating (MMP) platform, PolyPid develops long?acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer?formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.